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Abstract
Objective: Frascati international research criteria for HIV-associated neurocognitive disorders (HAND) are
controversial; some investigators have argued that Frascati criteria are too liberal, resulting in a high false positive
rate. Meyer et al. recommended more conservative revisions to HAND criteria, including exploring other commonly
used methodologies for neurocognitive impairment (NCI) in HIV including the global deficit score (GDS). This study
compares NCI classifications by Frascati, Meyer, and GDS methods, in relation to neuroimaging markers of brain
integrity in HIV. Method: Two hundred forty-one people living with HIV (PLWH) without current substance use
disorder or severe (confounding) comorbid conditions underwent comprehensive neurocognitive testing and brain
structural magnetic resonance imaging and magnetic resonance spectroscopy. Participants were classified using
Frascati criteria versus Meyer criteria: concordant unimpaired [Frascati(Un)/Meyer(Un)], concordant impaired
[Frascati(Imp)/Meyer(Imp)], or discordant [Frascati(Imp)/Meyer(Un)] which were impaired via Frascati criteria
but unimpaired via Meyer criteria. To investigate the GDS versus Meyer criteria, the same groupings were utilized
using GDS criteria instead of Frascati criteria. Results: When examining Frascati versus Meyer criteria, discordant
Frascati(Imp)/Meyer(Un) individuals had less cortical gray matter, greater sulcal cerebrospinal fluid volume, and
greater evidence of neuroinflammation (i.e., choline) than concordant Frascati(Un)/Meyer(Un) individuals. GDS
versus Meyer comparisons indicated that discordant GDS(Imp)/Meyer(Un) individuals had less cortical gray matter
and lower levels of energy metabolism (i.e., creatine) than concordant GDS(Un)/Meyer(Un) individuals. In both
sets of analyses, the discordant group did not differ from the concordant impaired group on any neuroimaging
measure. Conclusions: The Meyer criteria failed to capture a substantial portion of PLWH with brain
abnormalities. These findings support continued use of Frascati or GDS criteria to detect HIV-associated CNS
dysfunction.
Keywords: Magnetic resonance imaging, Magnetic resonance spectroscopy, Cognition, Infectious disease, HIV-associated
neurocognitive disorders, Frascati criteria
INTRODUCTION
Since the introduction of combination antiretroviral therapy
(cART), life expectancies among people living with HIV
(PLWH) have increased, while rates of medical morbidity
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andmortality have decreased. However, HIV-associated neu-
rocognitive disorders (HAND), especially milder forms of
neurocognitive impairment (NCI), have persisted in the
cART era (Heaton et al., 2011). Frascati criteria, the current
international research nosology for HAND, were developed
to meet the need for updated, operationalized classification
methods, especially as literature emerged showing that even
mild NCI in HIV was associated with a range of unfavorable
functional outcomes (Antinori et al., 2007). Using Frascati
criteria, HAND prevalence ranges from 30 to 50%, depend-
ing on comorbidities and HIV disease treatment histories
(Heaton et al., 2010; Saloner & Cysique, 2017). The majority
of those with HAND are classified with mild-to-moderate
impairment (>1 SD below the mean in two cognitive
domains), which is further divided into asymptomatic neuro-
cognitive impairment (ANI; meeting criteria for cognitive,
but not functional decline) and mild neurocognitive disorder
(MND; meeting criteria for both cognitive and functional
decline; Antinori et al., 2007).
There remains controversy regarding Frascati criteria’s
clinical applicability. Some investigators have proposed that
the Frascati criteria for milder HAND are too liberal, resulting
in high false positive classifications, overestimation of HAND,
and undue distress for patients (Gisslén, Price, & Nilsson,
2011; Meyer, Boscardin, Kwasa, & Price, 2013; Torti, Focà,
Cesana, & Lescure, 2011). Consequently, Meyer et al.
(2013) advocate for stricter cognitive impairment cutoffs
(1.5 SD below the mean) and a smaller test battery (i.e., 3–5
domains versus 7 domains). Although false positive misclassi-
fications may result in adverse consequences, detecting HIV-
associated neurological dysfunction at its earliest point may
be important for early intervention. For example, detection of
early CNS dysfunction may allow for cognitive neurorehabili-
tation interventions and mitigate risk for NCI-related adverse
functional outcomes (Iudicello, Hussain, Watson, Morgan, &
Heaton, 2019). In addition, constraining cutoffs to 1.5 SD
below the mean may result in a loss of sensitivity for detecting
brain disorders (Heaton, Miller, Taylor, & Grant, 2004; Heaton
et al., 2004) and the probability that PLWH with clinically
significant neurocognitive difficulties may be overlooked.
An alternate, slightly more conservative approach relative
to Frascati for detecting NCI in PLWH is the global deficit
score (GDS; Carey et al., 2004) method. The GDS, an objec-
tive, algorithmic approach to classifying NCI, is often used in
research settings and has demonstrated reliability in detecting
NCI in HIV (Cysique et al., 2010; Heaton et al., 1995;
Kabuba, Anitha Menon, Franklin, Heaton, & Hestad, 2017;
Kanmogne et al., 2010) and is related to functional- and
health-related outcomes (Andrade et al., 2013; Hinkin
et al., 2004). The GDS is a weighted average of neuropsycho-
logical test deficit scores ranging from 0 (no impairment) to 5
(severe impairment); therefore, it considers both number and
severity of deficits. Blackstone et al. (2012) illustrated that
GDS-determined NCI nearly guarantees meeting Frascati cri-
teria for mild NCI, though the opposite is not necessarily true.
Additionally, those impaired using only Frascati criteria had
less neurocognitive and functional deficits than those
impaired using the GDS methodology, further suggesting
the GDS approach is more conservative than Frascati criteria.
In addition to neurocognitive assessment, non-invasive
magnetic resonance imaging (MRI) techniques have
enhanced understanding of HIV-related brain abnormalities
and may have potential in diagnosing HAND, as there is
no reliable biomarker correlate of HAND. Structural MRI
studies report cortical and subcortical gray matter atrophy
and white matter atrophy as well as increased abnormal white
matter volume, and these findings have persisted into the
cART era (Becker et al., 2012; Kallianpur et al., 2013;
Nichols et al., 2019). With respect to cognitive functioning,
greater brain atrophy correlates with widespread neurocogni-
tive deficits (Alakkas et al., 2018; Bonnet et al., 2013; Cohen
et al., 2010; Patel et al., 2002; Thames et al., 2012). Magnetic
resonance spectroscopy (MRS) studies demonstrate cerebral
metabolic abnormalities indicative of neuroinflammation
(e.g., elevated choline and myo-inositol) and neuronal loss
(e.g., reduced N-acetyl-aspartate and glutamate) across cort-
ical and subcortical tissues (Chang et al., 2004; Cysique et al.,
2013; Ernst, Jiang, Nakama, Buchthal, & Chang, 2010;
Harezlak et al., 2011; Paul et al., 2008). PLWHwith the great-
est evidence of neuroinflammation and neuronal loss are at
higher risk for HAND, with decrements in executive func-
tion, working memory, learning, recall, and complex motor
skills (Ernst et al., 2010; Mohamed, Barker et al., 2010;
Mohamed, Barker, Skolasky, & Sacktor, 2018; Paul et al.,
2008). Given these findings, some authors have advocated
for the inclusion of neuroimaging biomarkers in HAND diag-
nostic decision-making (Ances & Hammoud, 2014; Masters
& Ances, 2014; Saloner & Cysique, 2017).
Those who have criticized current HAND nosology sug-
gest Frascati criteria over-diagnose HAND, potentially
resulting in a decrease in power to detect associations
between HAND and imaging markers (Meyer et al., 2013;
Torti et al., 2011). However, analyses of neuroimaging data
have not been reported. Therefore, the current study aims to
examine structural and metabolite brain imaging markers in
PLWH who are impaired via Frascati criteria but unimpaired
via Meyer criteria compared to those that are concordantly
unimpaired and concordantly impaired. Additionally,
Meyer et al. (2013) recommended exploring other commonly
used classifications, including the GDS; therefore, we also
examined those that are impaired via GDS but unimpaired
via Meyer criteria compared to those that are concordanly
unimpaired or concordantly impaired. These findings may
help determine if discrepantly classified PLWH exhibit
neuroanatomical profiles that more closely resemble the con-
cordantly impaired or the concordanly unimpared groups.
METHODS
Participants
The present cross-sectional study included 241 PLWH in the
NIH-funded CNS HIV Anti-Retroviral Therapy Effects
Research (CHARTER) study who completed comprehensive
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neuropsychological testing, neuromedical assessment, and
high-resolution multichannel structural MRI and MRS
between 2004 and 2007 (Jernigan et al., 2011). Participants
were excluded from analysis if there was evidence of severe
confounding comorbid conditions as described in Antinori
et al. (2007) and Heaton et al. (2010), current substance
use disorder, or insufficient neuropsychological data.
Additionally, one participant was excluded for meeting criteria
for Meyer impairment but being classified as unimpaired via
Frascati criteria (see Supplemental Figure 1).
Participants were recruited and examined at one of five
sites: Johns Hopkins University (Baltimore, MD, n= 38);
Icahn School of Medicine at Mount Sinai (New York, NY,
n= 56); University of California, San Diego (San Diego,
CA, n= 68); University of Texas Medical Branch
(Galveston, TX, n= 53); and University of Washington
(Seattle, WA, n= 26). The procedures were approved by
the Institutional Review Board at each university, and all
participants provided written informed consent.
Neuropsychological Assessment
Participants completed comprehensive neuropsychological
testing, which assesses seven cognitive domains commonly
affected by HIV (verbal fluency, working memory, speed
of information processing, executive functioning, learning,
recall, and motor). Specific tests are described in detail in
Heaton et al., 2010. Raw test scores were converted to
T-scores corrected for the effects of age, education, sex,
and race (Heaton et al., 2004; Heaton, Taylor, & Manly,
2003; Norman et al., 2011).
Clinical ratings (Frascati criteria)
As referenced in the Antinori et al. (2007) presentation of
Frascati criteria, clinical ratings (CR) are described in detail
by Woods et al. (2004). Demographically corrected T-scores
were not averaged per domain to obtain a domain T-score,
which would allow a good score on one test to obscure or
offset a very poor score on another test. Instead, more weight
is given to the most impaired scores per domain: if there are
two domain scores at that level, this defines the level of the
domain, whereas if there is only one score at that level the
domain rating is one rating score less (Woods et al., 2004).
Tests and domains were then assigned a CR, using a 9-point
scale ranging from 1 (i.e., above average functioning) to 9
(i.e., severe impairment). Performance in a domain is
considered to be impaired if the domain CR is greater than
or equal to 5 (CR of 5 is defined as “mild impairment” and
is equivalent to a T-score of 35–39). A participant was
classified with HAND if at least two domains of the seven
domains assessed were in the impaired range (i.e., CR≥5).
However, if learning and memory were the only impaired
domains, the participant had to demonstrate impaired recall
retention (i.e., forgetting or impaired retrieval) as well as
impaired learning, in order to avoid double-penalization for
learning deficits. The CR methodology operationalizes and
is consistent with current Frascati criteria for classifying
HAND (Antinori et al., 2007).
The 13-item Lawton-Brody ADL questionnaire (Lawton
& Brody, 1969) was used to assess functional impairment
(vs. best level of prior functioning) in performing instrumental
activities of daily living. The 33-item Patient’s Assessment
of Own Functioning (PAOFI; Chelune, Heaton, & Lehman,
1986) was used to assess current cognitive difficulties in
everyday life. Functional decline was defined as at least two
types of evidence of decreased everyday functioning. Those
who were classified as impaired using Frascati CR guidelines
were classified with ANI, MND, or HIV-associated dementia
(HAD). In line with Frascati criteria described in Antinori et al.
(2007), those demonstratingmildNCI (i.e., at least 1 SD below
the mean in at least two cognitive domains) but not endorsing
functional impairment were classified as ANI, those
demonstrating mild NCI and also endorsing decline in func-
tional abilities were classified as MND, and those with major
NCI (i.e., at least 2 SD below the mean in at least two
cognitive domains) and more severe functional decline were
classified as HAD (Figure 1).
Meyer criteria
Meyer et al. (2013) recommend analyses be limited to three
to five cognitive domains, the threshold for impairment be
lowered to less than or equal to−1.5 standard deviations below
the demographically corrected mean, and the average domain
score be used to define an “abnormal” domain. Meyer et al.
(2013) do not recommend which domains be removed from
consideration; we selected verbal fluency and speed of informa-
tion processing as these domains show the lowest prevalence of
impairment in HIV (Heaton et al., 2011), leaving five cognitive
domains (learning, delayed recall, working memory, complex
motor, and executive function). Individual test T-scores were
averaged in each domain to create domain T-scores, and a



























Normal ANI MND HAD
Frascati(Un)/Meyer(Un) Frascati(Imp)/Meyer(Imp)Frascati(Imp)/Meyer(Un)
Fig. 1. Distribution of subjects per group using Frascati Clinical Rating
versusMeyer Criteria.Note. Frascati(Un)/Meyer(Un)=Unimpaired by
both criteria; Frascati(Imp)/Meyer(Un)= Impaired by Frascati criteria
and Unimpaired by Meyer; Frascati(Imp)/Meyer(Imp)= Impaired
by both criteria. HAND subtypes defined using Frascati criteria:
ANI= asymptomatic neurocognitive impairment; MND=mild
neurocognitive disorder; HAD=HIV-associated dementia.
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least two domains had an average T-score of less than or equal
to 35 (equivalent to Meyer’s recommendations of≤−1.5 stan-
dard deviations below the average domain score). Participants
were categorized into three groups for Frascati CR versus
Meyer analyses: (1) a dually unimpaired group [Frascati-
(Un)/Meyer(Un)]: unimpaired by Frascati CR and Meyer
criteria; (2) Frascati CR-only impairment [Frascati(Imp)/
Meyer(Un)]: impaired by FrascatiCRbut unimpaired byMeyer
criteria; and (3) a dually impaired group [Frascati(Imp)/
Meyer(Imp)]: impaired by Frascati CR and Meyer criteria.
Global Deficit Score (GDS)
To generate the GDS, individual test T-scores were first con-
verted to deficit scores, which range from 0 (T-score≥ 40;
unimpaired) to 5 (T< 20; severely impaired). Deficit scores
were averaged across all tests in the seven domains assessed
to obtain a GDS and global impairment was defined by a
GDS≥ 0.5. To compare patterns of impairment by domain,
tests in each domain were averaged to obtain a domain deficit
score (DDS); an impaired domain was defined as a
DDS> 0.5. These cutoffs are commonly utilized and have
previously been shown to yield the best sensitivity to
specificity ratio (Carey et al., 2004; Heaton et al., 2004).
Participants were categorized into three groups for GDS
versus Meyer analyses: (1) a dually unimpaired group
[GDS(Un)/Meyer(Un)]: unimpaired by GDS and Meyer
criteria; (2) GDS-only impairment [GDS(Imp)/Meyer(Un)]:
impaired by GDS but unimpaired by Meyer criteria; and
(3) a dually impaired group [GDS(Imp)/Meyer(Imp)]:
impaired using both Meyer and GDS criteria (Figure 2).
Cognitive reserve variables
Participants also were administered the Reading Subtest from
the Wide Range Achievement Test-3 (WRAT; Wilkinson,
1993). The WRAT is a reliable estimator of premorbid
IQ, despite cognitive decline associated with HIV-
infection (Casaletto et al., 2014; Olsen et al., 2015).
Additionally, the Hollingshead Index of Social Status
(Hollingshead, 1975) was calculated using a weighted
average of educational and occupational attainment.
Neuromedical and Psychiatric Assessment
Medical history and HIV disease history were gathered
via standardized neuromedical evaluation. Common
medical comorbidities listed in Tables 1 and 2 were
determined by self-report or taking medication for the
condition. Psychiatric comorbidities were assessed using
the Composite International Diagnostic Interview (World
Health Organization, 1997), which is a computer-based,
fully structured interview to assess lifetime and current
affective and substance use disorders in line with the
Diagnostic and Statistical Manual of Mental Disorders-
IV (DSM-IV). A senior clinician (R.K.H.) reviewed all
medical, educational, and psychiatric histories to classify
each participant into comorbidity subgroups as defined
by Antinori et al. (2007) and Heaton et al. (2010).
Participants with severe comorbidities were classified
as “confounded” and were excluded from this study.
Participants with mild-to-moderate comorbidities were
classified as having “contributing” comorbidities and
were included in this study. These mild-to-moderate co-
morbidities could have contributed to NCI, but the timing
or severity of the NCI suggests an HIV component. The
remainder had no more than minimal comorbidities that
were considered “incidental” to a HAND diagnosis.
Nadir CD4þT-cell count was estimated via a combination
of self-report and medical records. Current CD4þ T-cell
count was measured with flow cytometry, and HIV RNA
level was measured by ultra-sensitive PCR (Amplicor,
Roche Diagnostic System, Indianapolis IN; lower limit of
detection <50 copies/ml) in a CLIA-certified clinical
laboratory.
Neuroimaging Assessments
MRI data were acquired on six General Electric 1.5-Tesla
scanners across five sites, annually reviewed for quality;
because scanner differences (e.g., hardware upgrades) can
influence neuroimaging measurements, we included a
“scanner” variable in statistical analyses to account for these
effects between sites (Fennema-Notestine et al., 2007) as in
our prior work (Fennema-Notestine et al., 2013; Jernigan
et al., 2011). Four series were acquired for structural
morphometric analysis: coronal two-dimensional T2- and
proton-density (PD)-weighted fast spin echo sequences
(section thickness = 2.0 mm), and three-dimensional sagittal
T1- and PD-weighted spoiled gradient recalled acquisitions
(section thickness= 1.3 mm; as in Fennema-Notestine

































Fig. 2. Distribution of subjects per group using GDS versus Meyer
Criteria. Note. Depicts number of participants that were previously
Frascati(Imp)/Meyer(Un) via Frascati versus Meyer Criteria and are
GDS(Un)/Meyer(Un) via GDS versus Meyer Criteria (n= 30) and
those that were Frascati(Un)/Meyer(Un) via Frascati versus Meyer
Criteria and GDS(Un)/Meyer(Un) via GDS versus Meyer criteria
(n= 2).
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a standardized point-resolved spectroscopy protocol (echo
time= 35 ms, repetition time= 3000 ms; as in Anderson
et al., 2015).
Multi-channel structural MRI
As described previously (Fennema-Notestine et al., 2013;
Jernigan et al., 2011), we used the multi-channel structural
images in a semi-automated workflow to measure cortical
and subcortical gray matter; total cerebral and abnormal
(e.g., hyperintense regions on T2-weighted images) white
matter; and ventricular and cerebral sulcal CSF, as well as
supra-tentorial cranial vault volume to account for individual
differences in head size. The workflow includes inspection
for motion and other artifacts, re-slicing to a standard space,
intrasubject mutual information registration, bias-correction
with nonparametric non-uniformity normalization, removal of
non-brain tissue, three-tissue segmentation (gray matter, white
matter, and CSF), abnormal white matter designation, and ana-
tomical labeling performed by trained anatomists. This approach







Median [IQR], Mean (SD),
or n (%)
Median [IQR], Mean
(SD), or n (%)
Median [IQR], Mean




Age (years) 46.0 (8.3) 43.1 (7.6) 44.6 (7.4) .10
Gender (male) 120 (83.3%) 49 (76.6%) 25 (75.8%) .40
Ethnicity .06
Non-Hispanic white 60 (41.7%) 25 (39.1%) 16 (48.5%)
African American 72 (50.0%) 28 (43.8%) 9 (27.3%)
Hispanic 10 (6.9%) 10 (15.6%) 8 (24.2%)
Other 2 (1.4%) 1 (1.6%) 0 (0.0%)
Education (years) 12.9 (2.3) 12.9 (2.6) 14.2 (2.3) .02 I/I> I/U, U/U
WRAT-3 Reading 97.0 (13.2) 93.0 (13.2) 93.2 (14.0) .10
Hollingsheadb 40.4 (10.7) 40.3 (11.5) 38.4 (13.4) .63
Employed 50 (34.7%) 17 (26.6%) 13 (39.4%) .37
HIV disease characteristics
History of AIDS 97 (67.4%) 43 (67.2%) 24 (72.7%) .82
Detectable viral loadc 73 (50.7%) 30 (47.6%) 13 (40.6%) .58
Current CD4 count 442 [266–611] 463 [329–630] 516 [268–667] .55
Nadir CD4 count 150 [30–300] 172 [19–277] 109 [28–224] .50
Estimated duration of
infection (years)
11.0 [5.8–15.6] 13.3 [4.8–17.0] 12.7 [6.2–15.3] .47
On ART 107 (74.3%) 50 (78.1%) 31 (93.9%) .05
Failing ART (%
detectable on ART)
38 (35.5%) 18 (36.0%) 11 (36.7%) .99
Medical comorbidities and characteristics
Hypertensiond 20 (14.6%) 13 (21.0%) 9 (28.1%) .16
Hyperlipidemiad 12 (8.8%) 9 (14.5%) 5 (15.6%) .25
Hepatitis Cd 41 (29.9%) 18 (29.0%) 9 (28.1%) .98
Diabetesd 14 (10.2%) 9 (14.5%) 4 (12.5%) .67
Psychiatric diagnoses
LT MDD 80 (55.6%) 37 (57.8%) 19 (57.6%) .95
Current MDDe 14 (9.7%) 8 (12.7%) 1 (3.0%) .31
LT SUD 111 (77.1%) 46 (71.9%) 19 (57.6%) .07
LT alcohol 83 (57.6%) 32 (50.0%) 14 (42.4%) .23
LT cannabis 42 (29.2%) 17 (26.6%) 7 (21.2%) .64
LT methamphetamine 25 (17.4%) 11 (17.2%) 5 (15.2%) .95
Contributing diagnoses 35 (24.3%) 20 (31.3%) 18 (54.6%) <.01 I/I>U/U
Note. Frascati(Un)/Meyer(Un)=Unimpaired by both criteria; Frascati(Imp)/Meyer(Un)= Impaired by Frascati CR criteria and Unimpaired by Meyer;
Frascati(Imp)/Meyer(Imp)= Impaired by both criteria.WRAT=Wide RangeAchievement Test, third edition; ART= antiretroviral therapy; BMI= bodymass
index; LT= lifetime; MDD=major depressive disorder; SUD= substance use disorder.
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includes the identification of cerebral white matter regions with
abnormal MRI signal characteristics that are segmented as gray
matter but anatomically located within the white matter.
Single-voxel MRS
As described previously (Anderson et al., 2015), three voxels
were acquired: frontal gray matter (20 × 20 × 20 mm and 64
acquisitions), frontal white matter (20 × 20 × 20 mm and 64
acquisitions), and basal ganglia (20 × 20 × 15mm and 96
acquisitions). MRS concentrations of N-acetyl-aspartate,
choline, myo-inositol, and creatine were quantified using
LCModel with water suppression (Provencher, 2001).
Water suppression allows for examination of absolute
metabolite levels; although ratios to creatine have been
commonly reported in the past for standardization across sites
and studies, that approach is limited by evidence that HIV
infection independently affects creatine levels directly,
confounding the interpretation of ratio values and existing
findings (as in Anderson et al., 2015; Jansen, Backes,








(SD), or n (%)
Median [IQR], Mean
(SD), or n (%)
Median [IQR], Mean




Age (years) 43.4 (7.8) 44.4 (6.1) 44.6 (7.4) .17
Gender (male) 141 (82.0%) 28 (77.8%) 25 (75.8%) .64
Ethnicity .09
Non-Hispanic white 69 (40.1%) 16 (44.4%) 16 (48.5%)
African American 85 (49.4%) 15 (41.7%) 9 (27.3%)
Hispanic 15 (8.7%) 5 (13.9%) 8 (24.2%)
Other 3 (1.7%) 0 (0.0%) 0 (0.0%)
Education (years) 12.8 (2.4) 13.3 (2.5) 14.2 (2.3) <.01 I/I>U/U
WRAT 96.6 (13.0) 91.7 (16.4) 93.2 (14.0) .09
Hollingsheadb 40.5 (10.7) 39.9 (12.2) 38.4 (13.4) .60
Employed 56 (32.6%) 11 (30.6%) 13 (39.3%) .70
HIV disease characteristics
History of AIDS 115 (66.9%) 25 (69.4%) 24 (72.7%) .79
Detectable viral loadc 86 (50.3%) 17 (47.2%) 13 (40.6%) .60
Current CD4 count 450 [267–621] 477 [359–630] 516 [268–667] .35
Nadir CD4 count 150 [36–300] 155 [14–277] 109 [28–224] .36
Estimated duration of
infection (years)
11.2 [5.7–15.6] 14.3 [5.0–17.9] 12.7 [6.2–15.3] .40
On ART 127 (73.8%) 30 (83.3%) 31 (93.9%) .03 I/I>U/U
Failing ART (%
detectable on ART)
45 (35.4%) 11 (36.7%) 11 (36.7%) .99
Medical comorbidities and characteristics
Hypertensiond 24 (14.6%) 9 (25.7%) 9 (28.1%) .09
Hyperlipidemiad 16 (9.8%) 5 (14.3%) 5 (15.6%) .52
Hepatitis Cd 50 (30.5%) 9 (25.7%) 9 (28.1%) .84
Diabetesd 18 (11.0%) 5 (14.3%) 4 (12.5%) .85
Psychiatric diagnoses
LT MDD 95 (55.2%) 22 (61.1%) 19 (57.6%) .80
Current MDDe 15 (8.7%) 7 (20.0%) 1 (3.0%) .05
LT SUD 131 (76.2%) 26 (72.2%) 19 (57.6%) .09
LT alcohol 98 (57.0%) 17 (47.2%) 14 (42.4%) .22
LT cannabis 51 (29.7%) 8 (22.2%) 7 (21.2%) .46
LT methamphetamine 30 (17.4%) 6 (16.7%) 5 (15.2%) .95
Contributing diagnoses 43 (25.0%) 12 (33.3%) 18 (54.6%) <.01 I/I>U/U
Note. GDS(Un)/Meyer(Un)=Unimpaired by both Meyer and GDS criteria; GDS(Imp)/Meyer(Un)= Impaired by GDS criteria and Unimpaired by Meyer;
GDS(Imp)/Meyer(Imp)= impaired by both criteria. WRAT=Wide Range Achievement Test, third edition; ART= antiretroviral therapy; BMI= body mass
index; LT= lifetime; MDD=major depressive disorder; SUD= substance use disorder.
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Nicolay, & Kooi, 2006). Only metabolite estimates for
adequate spectra (standard deviation < 21) were used; there-
fore, sample size varied by MRS metabolite. Structural
segmentation was used to estimate the proportion of relevant
tissue volume within each MRS voxel (e.g., amount of gray
matter in frontal graymatter voxel) to control for variability in
individual sampling.
Statistical Analyses
First, ANOVAs or Kruskal-Wallis tests for continuous variables
and Chi-square tests for categorical variables were used in order
to compare both Frascati CR versus Meyer and GDS versus
Meyer group differences on demographics, HIV disease charac-
teristics, medical comorbidities, and psychiatric diagnoses. To
control for multiple comparisons, Tukey’s Honest Significant
Difference test was applied to ANOVA tests, and Bonferroni
correction was applied for Kruskal-Wallis and Chi-square tests.
Multivariable linear regression analyses were performed to
examine the associations between group and log-transformed
MRI structural volumes and MRS metabolites. Both age
and scanner were included as covariates in every model.
Additionally, supratentorial cranial vault volume was included
inmodels predictingMRI structural volume analyses to control
for differences in head size, and proportion of relevant tissue in
each voxel was included in MRS analyses. Standardized beta
coefficients are reported in text and tables. For significant
findings, an effect size that is analogous to Cohen’s d was
estimated by dividing the regression coefficient by the residual
standard deviation. These analyses were run twice: once to
compare groups using Frascati CR and Meyer criteria, and
again to compare GDS and Meyer criteria. In all multivariable
linear regression analyses, the impaired/unimpaired group was
specified as the reference group to compare differences
between the concordant impaired and concordant unimpaired
groups. JMP version 13.0.0 was used for all analyses.
RESULTS
Sample Characteristics
Most participants were non-Hispanic white men with an aver-
age age of 43.9 years and13.1 years of education.About 78%of
participantswere being prescribed antiretroviral therapy (ART),
and 51% were virally suppressed (i.e., <50 copies/ml plasma).
Frascati CR versus Meyer criteria
Participants’ characteristics by Frascati CR versus Meyer
Impairment grouping are displayed in Table 1. The groups
had similar demographics, HIV disease characteristics, medi-
cal comorbidities, and psychiatric diagnoses. However, after
correcting for multiple comparisons, the Frascati(Imp)/
Meyer(Imp) group had higher average education than both
the Frascati(Un)/Meyer(Un) and Frascati(Imp)/Meyer(Un)
groups, and the Frascati(Imp)/Meyer(Imp) group had a
greater proportion classified with contributing comorbidities
than the Frascati(Un)/Meyer(Un) group. Of note, the propor-
tion of those demonstrating evidence of functional impair-
ment and classified as MND or HAD (Figure 1) was
similar in the Frascati(Imp)/Meyer(Un) group (45.3%) and
Frascati(Imp)/Meyer(Imp) group (42.4%); put another way,
29.9% of the functionally impaired participants in the
Frascati(Imp) group were classified as normal by the
Meyer criteria. Proportion impaired, as defined by a CR of
≥5, in each cognitive domain by group is displayed in
Figure 3. A stair-step pattern (Frascati(Un)/Meyer(Un)-






























Fig. 3. Neuropsychological impairment rates by clinical rating (CR; Frascati) versus Meyer group. Note. Frascati(Un)/
Meyer(Un)=Unimpaired by both criteria; Frascati(Imp)/Meyer(Un)= Impaired by Frascati CR criteria and Unimpaired by Meyer;
Frascati(Imp)/Meyer(Imp)= Impaired by both criteria. Impairment defined as a CR≥ 5. *Domain not included in Meyer criteria
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observed for all domains except for verbal fluency in which
the Frascati(Imp)/Meyer(Un) and Frascati(Imp)/Meyer(Imp)
groups had similar rates of impairment.
GDS versus Meyer criteria
Participants’ characteristics by GDS versus Meyer
Impairment grouping are displayed in Table 2. The groups
were similar on most characteristics; however, the
GDS(Imp)/Meyer(Imp) group had more education, a greater
proportion prescribed antiretroviral therapy, and a greater
proportion of those classified as having contributing
comorbidities than the GDS(Un)/Meyer(Un) group. Thirty
of 64 participants (46.9%) who were categorized as
Frascati(Imp)/Meyer(Un) using Frascati CR criteria were
classified as GDS(Un)/Meyer(Un) using GDS methodology,
and 2 of 144 (1.4%) participants who were previously
classified as Frascati(Un)/Meyer(Un) using Frascati CR
criteria were classified as GDS(Imp)/Meyer(Un) using
GDS methodology (Figure 2). Proportion impaired, as
defined by DDS > 0.5, in each cognitive domain by group
is displayed in Figure 4. A similar stair-step pattern of
proportion impaired GDS(Un)/Meyer(Un) <GDS(Imp)/
Meyer(Un) <GDS(Imp)/Meyer(Imp) was observed for all
cognitive domains except for verbal fluency.
Frascati CR versus Meyer Criteria Imaging
Measures
Standardized beta coefficients (β) from the linear regression
models predicting structural MRI and MRS variables that
compare Frascati CR versus Meyer Frascati(Un)/Meyer(Un)
and Frascati(Imp)/Meyer(Imp) groups to the Frascati(Un)/
Meyer(Imp) group are displayed in Table 3, and predicted
means and effect sizes from the significant finding are
displayed in Figure 5.
Structural MRI
After adjusting for scanner, age, and cerebral vault volume,
the Frascati(Imp)/Meyer(Un) group had less cortical gray
matter volume (β= 0.08, p= .02) and more sulcal CSF
volume (β=−0.14, p= .04) than the Frascati(Un)/
Meyer(Un) group. The Frascati(Imp)/Meyer(Un) group did
not significantly differ from the Frascati(Imp)/Meyer(Imp)
on any MRI structural variables.
MRS
After accounting for relevant covariates, choline in the frontal
gray matter was significantly greater in the Frascati(Imp)/
Meyer(Un) group compared to the Frascati(Un)/Meyer(Un)
group (β=−0.17, p= .01). The Frascati(Imp)/Meyer(Un)
group also tended to have higher choline in frontal gray
matter than the Frascati(Imp)/Meyer(Imp) group, but this
was not significant (β=−0.12, p= .08) nor did any other
Frascati(Imp)/Meyer(Un) versus Frascati(Imp)/Meyer(Imp)
MRS metabolite comparisons differ significantly.
GDS versus Meyer Criteria Imaging Measures
Standardized beta coefficients (β) from the linear regression
models predicting structural MRI and MRS variables
that compare GDS versus Meyer GDS(Un)/Meyer(Un)
and GDS(Imp)/Meyer(Imp) groups to the GDS(Un)/
Meyer(Imp) group are displayed in Table 4, and predicted
means and effect sizes from the significant finding are
displayed in Figure 6.
Structural MRI
When analyzing the structural MRI variables using the GDS
versus Meyer criteria, the GDS(Imp)/Meyer(Un) group had
































Fig. 4. Neuropsychological impairment rates by GDS versus Meyer group. GDS(Un)/Meyer(Un)=Unimpaired by both Meyer and GDS
criteria; GDS(Imp)/Meyer(Un)= Impaired by GDS criteria and Unimpaired by Meyer; GDS(Imp)/Meyer(Imp)= impaired by both criteria.
Note. Impairment defined as a domain deficit score (DDS)> 0.5. *Domain not included in Meyer criteria.
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Frascati(Un)/Meyer(Un) 0.082* 0.013 −0.046 0.024 −0.102 −0.135*
Frascati(Imp)/Meyer(Imp) −0.004 −0.053 0.080 −0.039 0.051 0.016
N-acetyl
aspartate Choline Creatine Myo-inositol Glutamate
MRS frontal white matter
Frascati(Un)/Meyer(Un) 0.033 −0.051 0.097 0.016 −0.089
Frascati(Imp)/Meyer(Imp) −0.053 −0.012 0.033 −0.025 −0.073
MRS frontal gray matter
Frascati(Un)/Meyer(Un) −0.009 −0.173* −0.010 0.016 −0.021
Frascati(Imp)/Meyer(Imp) −0.066 −0.119 −0.027 0.005 −0.052
MRS basal ganglia
Frascati(Un)/Meyer(Un) 0.118 −0.067 0.030 −0.125 0.050
Frascati(Imp)/Meyer(Imp) −0.039 −0.064 −0.006 −0.066 −0.013
Note. Frascati(Un)/Meyer(Un)=Unimpaired by both criteria; Frascati(Imp)/Meyer(Un)= Impaired by Frascati CR criteria and Unimpaired by Meyer;
Frascati(Imp)/Meyer(Imp)= Impaired by both criteria. CSF= cerebrospinal fluid.
All analyses were in comparison to the Frascati(Imp)/Meyer(Un) group derived from Frascati CR versusMeyer criteria. Predictedmeans for significant relation-


























adj. d = 0.37
p = 0.90






















adj. d = 0.32
p = 0.80



























adj. d = 0.40 
p = 0.09
adj. d = 0.38 
Fig. 5. Predictedmeans with error bars denoting standard error for cortical graymatter volume (log), sulcal CSF volume (log), and frontal gray
matter choline for the Frascati CR versus Meyer groups. Note. Un/Un=Unimpaired by both criteria; Imp/Un= Impaired by Frascati CR
criteria and Unimpaired by Meyer; Imp/Imp= Impaired by both criteria; adj. d= adjusted Cohen’s d. The Frascati(Imp)/Meyer(Un) group
had less cortical gray matter, greater sulcal CSF volume, and greater FGM choline than the Frascati(Un)/Meyer(Un) group. The Frascati(Imp)/
Meyer(Un) group did not significantly differ from the Frascati(Imp)/Meyer(Imp) group on these measures.
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GDS(Un)/Meyer(Un) group (β= 0.9, p= .02), after adjusting
for covariates. As seen in the Frascati CR versus Meyer
criteria analyses, the GDS(Imp)/Meyer(Un) group did not
statistically differ from the GDS(Imp)/Meyer(Imp) group
on any MRI structural variables.
MRS
When comparing the groups derived from the GDS versus
Meyer criteria, the GDS(Imp)/Meyer(Un) group had signifi-
cantly less creatine in the frontal white matter than the
GDS(Un)/Meyer(Un) group (β= 0.18, p= .05). The
GDS(Imp)/Meyer(Un) and the GDS(Imp)/Meyer(Imp)
groups did not differ significantly on any MRS metabolites.
DISCUSSION
Optimal classification of NCI within the context of HIV
enables evaluation of potential mechanisms of CNS injury
and prediction of functional outcomes. It is also clinically
relevant, as false positive and false negative errors are both
important: false positive errors that are communicated to













GDS(Un)/Meyer(Un) 0.092* 0.108 −0.050 −0.034 −0.051 −0.074
GDS(Imp)/Meyer(Imp) 0.013 0.008 0.071 −0.071 0.069 0.035
N-acetyl
aspartate Choline Creatine Myo-inositol Glutamate
MRS frontal white matter
GDS(Un)/Meyer(Un) 0.000 −0.057 0.176* −0.019 −0.027
GDS(Imp)/Meyer(Imp) −0.069 −0.024 0.098 −0.046 −0.048
MRS frontal gray matter
GDS(Un)/Meyer(Un) 0.061 −0.016 0.106 0.052 0.065
GDS(Imp)/Meyer(Imp) −0.026 −0.051 0.081 0.030 −0.001
MRS basal ganglia
GDS(Un)/Meyer(Un) 0.087 −0.085 0.100 −0.136 0.044
GDS(Imp)/Meyer(Imp) −0.041 −0.084 0.038 −0.090 −0.009
Note. GDS(Un)/Meyer(Un)=Unimpaired by both Meyer and GDS criteria; GDS(Imp)/Meyer(Un)= Impaired by GDS criteria and Unimpaired by Meyer;
GDS(Imp)/Meyer(Imp)= impaired by both criteria. CSF= cerebrospinal fluid.
All analyses were in comparison to the GDS(Imp)/Meyer(Un) group derived from GDS versusMeyer criteria. Predicted means for significant relationships are



























adj. d = 0.45
p = 0.73



























adj. d = 0.40
p = 0.27
adj. d = 0.28
Fig. 6. Predicted means with error bars denoting standard error for cortical gray matter volume (log) and frontal white matter creatine for the
GDS versusMeyer groups.Note. Un/Un=Unimpaired by bothMeyer and GDS criteria; Imp/Un= Impaired by GDS criteria and Unimpaired
by Meyer; Imp/Imp= impaired by both criteria; adj. d= adjusted Cohen’s d. The GDS(Imp)/Meyer(Un) group had less cortical gray matter
and less FGM choline than the GDS(Un)/Meyer(Un) group. The GDS(Imp)/Meyer(Un) group did not significantly differ from the GDS(Imp)/
Meyer(Imp) group on these measures.
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patients could cause undue stress, and false negative diagno-
ses can result in missed opportunities to more closely monitor
or intervene. This study utilized neuroimaging to examine
different NCI criteria and help determine the optimal criteria
for detecting NCI within the context of HIV with regards to
brain integrity. Our findings indicate that those classified as
impaired using Frascati criteria or GDS criteria, but unim-
paired by the Meyer criteria, differ neuroanatomically from
those with unimpaired cognition. Based on these findings,
the Meyer criteria fail to capture a sizable group of PLWH
with cortical atrophy. The group that was not captured by
the Meyer criteria is not small; over a quarter (26%) of the
sample was in the discordant Frascati(Imp)/Meyer(Un) group
when classifying using Frascati CR, and 15% of the sample
was in the discordant GDS(Imp)/Meyer(Un) group when
classifying using GDS. While Meyer et al. (2013) are correct
that false positives will negatively affect power to detect asso-
ciations between cognitive impairment and brain integrity, it
is important to also note that false negatives reduce power as
well, which should be considered when examining optimal
NCI criteria within the context of HIV.
Consistent across the Frascati CR and GDS criteria, the
discordant group displayed similarly small cortical gray mat-
ter volumes compared to concordant impaired group, and sig-
nificantly smaller volumes of cortical gray matter compared
to the concordant unimpaired group. While it is difficult to
compare this study, which splits HAND into two groups
(i.e., Impaired/Unimpaired and Impaired/Impaired) to other
imaging studies examining HAND as one group, our findings
were somewhat consistent with other studies. Recent cART
era studies comparing neuroanatomical profiles of PLWH
to seronegative controls have identified cortical thinning, par-
ticularly in frontal and temporal structures, as a prevalent neu-
roimaging correlate within the context of HIV (Bonnet et al.,
2013; Cohen, Seider, &Navia, 2015; Thompson et al., 2005).
Additionally, these findings are consistent with a recent study
by the CHARTER group in an overlapping population that
found those classified as MND and HAD had smaller cortical
gray matter volumes relative to those without NCI (Alakkas
et al., 2018). Furthermore, reductions in frontal gray matter
have been detected in neurocognitively intact PLWH in the
absence of subcortical and white matter changes (Towgood
et al., 2012). Thus, while the Meyer criteria classify individ-
uals in the discordant Impaired/Unimpaired group as neuro-
cognitively unimpaired, the subtler neurocognitive deficits
defined by Frascati CR and GDS criteria may include early
HIV-related CNS injury. Although discordant Impaired/
Unimpaired individuals also displayed some evidence of
subcortical gray and white matter tissue injury compared to
concordant unimpaired individuals, these differences were
not statistically significant and are therefore consistent with
observations that PLWH in the cART era may be less
vulnerable to subcortical and white matter damage than the
pre-cART era (O’Connor, Zeffiro, & Zeffiro, 2018). Given
that our sample was characterized by high rates of impairment
in executive functioning, learning, and recall, it is not surpris-
ing that discordant Impaired/Unimpaired and concordant
unimpaired individuals were best differentiated by our esti-
mate of cortical gray matter volume, which encompasses
frontal and temporal structures that support memory and
higher-order thinking.
Discordant Impaired/Unimpaired individuals also dis-
played evidence of neurochemical abnormalities in cortical
gray and white matter tissues. For the Frascati CR versus
Meyer comparisons, the Frascati(Imp)/Meyer(Un) had higher
levels of choline, a marker of cellular membrane turnover
that is elevated with glial proliferation and neuroinflamma-
tory responses, in frontal gray matter than the concordant
unimpaired group. Previous research has shown that PLWH
display elevated levels of choline in the context of both
chronic-infection (Harezlak et al., 2011; Mohamed, Lentz
et al., 2010) and early infection (Lentz et al., 2011;
Valcour et al., 2012) compared to seronegative controls.
Research has also shown higher choline is associated with
worse neurocognitive functioning (Alakkas et al., 2018;
Chang et al., 2004; Paul et al., 2008). The neurocognitive
ramifications associated with choline may in part be mediated
by monocyte activation, a known driver of neural injury that
has been linked to choline in PLWH (Anderson et al., 2015;
Kamat et al., 2012; Lentz et al., 2011). However, while myo-
inositol, another marker of neuroinflammation, was greatest
in the Frascati(Imp)/Meyer(Un) group, this difference was
not statistically significant. Myo-inositol is more variable
than choline whenmeasured using a 1.5 Tesla scanner, so this
variability may be affecting our power to detect a significant
difference, or the neuroinflammatory differences between
groups may be more specific to choline. For the GDS versus
Meyer comparisons, the GDS(Imp)/Meyer(Un) group had
lower levels of creatine, a marker of brain energymetabolism,
in frontal white matter than the GDS(Un)/Meyer(Un) group.
Although creatine has been employed as a reference marker
in MRS studies to generate metabolite/creatine ratios (Jansen
et al., 2006), we have reported correlations between frontal
white matter creatine levels and HIV RNA in plasma and
CSF, nadir CD4 count, and CSF biomarkers of monocyte
and macrophage activation (Anderson et al., 2015). Thus,
the altered frontal white matter brain energy metabolism in
GDS(Imp)/Meyer(Un), compared to GDS(Un)/Meyer(Un)
individuals, may reflect neural dysfunction related to HIV-
associated neurotoxicity and neuroinflammation.
Analyses comparing impairment groupings’ demo-
graphics suggest that these three groups were fairly compa-
rable with the exception of formal educational attainment.
The concordant impaired group had the highest level of edu-
cation for both analyses. This is surprising given the ample
evidence showing that greater education is protective against
cognitive impairment in PLWH (Foley et al., 2012; Maki
et al., 2015; Tozzi et al., 2007). Education, which is often
used as a proxy variable for cognitive reserve, is a protective
factor against HAND (Morgan et al., 2012; Stern, Silva,
Chaisson, & Evans, 1996). However, cognitive reserve as
estimated from pre-morbid IQ (i.e., WRAT) and the
Hollingshead Index did not differ among the groups. In fact,
the concordant unimpaired group had the highest pre-morbid
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IQ but also had the lowest educational attainment. The
concordant impaired group had the most years (quantity)
of education, but the quality of their education and/or occupa-
tional attainment may have been lower. All neuropsychological
tests were adjusted for the effects of education; therefore, the
educational normative adjustments with T-scores (in the poten-
tial case of lower education quality) may be negatively
impacting the concordant impaired group resulting in greater
impairment rates.
The three groups were fairly similar on most HIV disease
characteristics. The concordant impaired group was more
likely to be on ART, but this was only significant in the
GDS versus Meyer comparisons and may result from earlier
policies that ART not be initiated until severe immuno-
suppression was detected. Of note, the proportion of those
on ART that were not virally suppressed did not differ
across groups. While the specific medical and psychiatric
comorbidities did not differ between the three groups, the
concordant impaired group had a greater proportion with
mild-to-moderate (i.e., “contributing” vs. “incidental”)
comorbidities compared to both the concordant unimpaired
and discordant groups. However, this comparison was
only significantly different with regard to the concordant
unimpaired group. We chose to exclude those with severe
(i.e., “confounded”) comorbidities, as confounding condi-
tions preclude diagnosis of HAND whereas contributing
conditions were included because they may exacerbate
HIV-associated NCI or brain abnormalities and NC impair-
ment, but are unlikely to fully account for them. This decision
is further supported by a recent neuroimaging study by the
CHARTER group, which found that those with “contribut-
ing” comorbidities were fairly comparable to those with
“incidental” comorbidities (Saloner et al., 2019). However,
greater comorbidity burden has been shown to increase risk
for impairment (Heaton et al., 2010; Patel et al., 2013), and
some groups have found comorbid conditions and socio-
demographic risk factors are associated with a greater risk
of NCI than HIV status (Maki et al., 2015). Additionally,
comorbidity burden may also contribute to volumetric abnor-
malities in PLWH (Masters & Ances, 2014; Lake et al.,
2017). Therefore, the concordant impaired group would be
expected to have more widespread cognitive impairments
and a higher prevalence of comorbidities and brain atrophy.
The aim of this study was to use neuroimaging to help assess
neurocognitive criteria for identifying CNS differences. This
study and the Meyer criteria do not address the relative con-
tribution of HIV versus comorbidities to the CNS difference.
Therefore, future studies that include an HIV-uninfected
comparison groups are needed to parse apart the effect of
HIV infection compared to comorbidities with respect to im-
aging measures and cognition.
Several limitations of our study should be considered. First,
this study was cross-sectional in nature; therefore, we cannot
make inferences with regard to causality or timing of NCI
in relation to structural or metabolic brain abnormalities.
Longitudinal studies examining long-term neuropsychological
outcomes of these groups in conjunction with imaging
measures are warranted. Next, because we did not study
HIV-uninfected controls, we cannot assess if the observed
associations are totally or primarily due to HIV infection;
therefore, these results should be interpreted within the context
of HIV rather than fully due to HIV. Additionally, while the
overall sample was fairly large, some groups, particularly
the concordant impaired group, had a smaller sample size.
Standardized betas were utilized in order to compare magni-
tude of the associations; however, this study may be under-
powered to observe some differences between the discordant
group and the concordant impaired group. Also, generalizabil-
ity of the current findings to other populations (e.g., to women)
should be considered. For example, this sample was predomi-
nantly men. Additionally, while the rate of viral suppression
was similar to Center for Disease Control and Prevention
(CDC) estimates for viral suppression in the United States,
viral suppression was somewhat lower than CDC estimates
for viral suppression of those engaged in medical care (80%
at <200 copies/ml; Center for Disease Control and
Prevention, 2016). Lastly, this study analyzed global measures
of brain structure acquired on 1.5 Tesla systems. Future studies
should utilize scannerswith greater field strength (e.g., 3 Tesla)
as well as examine specific brain structures and other imaging
modalities such as functional MRI and diffusion tensor imag-
ing that have been shown to be sensitive to cognitive function-
ing in HIV (Ances et al., 2009; Cysique et al., 2017; du Plessis
et al., 2017; Masters & Ances, 2014).
In a large group of demographically and geographically
diverse PLWH, we found that both Frascati and GDS criteria
captured a group of PLWHwith worse brain integrity as com-
pared to those without NCI. While Frascati and GDS criteria
may be improved by further research, these findings suggest
that the cutoff for mild impairment in HIV research studies
should remain at 1 SD below the mean (i.e., the cutoff used
in Frascati and GDS criteria). Future neuroimaging studies
that track and attempt to predict longitudinal progression
of HIV-related NCI are needed in order to assess the possible
clinical utility of neuroimaging in helping to identify those at
risk for HIV-related NCI.
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